Editing Abbott Laboratories (section)

===Depakote===
On 2 October 2012, the company was charged with a $500 million fine and $198.5 million forfeiture for illegal marketing of [[Depakote]] for uses not approved by the FDA. The court also sentenced Abbott to a five-year term of probation and court supervision.<ref name="doj">[https://www.justice.gov/opa/pr/2012/May/12-civ-585.html Abbott Labs to Pay $1.5 Billion to Resolve Criminal & Civil Investigations of Off-label Promotion of Depakote] {{Webarchive|url=https://web.archive.org/web/20140821040621/http://www.justice.gov/opa/pr/2012/May/12-civ-585.html |date=21 August 2014 }}, Press Release, [[United States Department of Justice]] Office of Public Affairs, 7 May 2012. Retrieved 17 August 2014.</ref> Shareholders then brought derivative suits against the company directors for breach of fiduciary duty.<ref>U.S. ex rel. McCoyd v. Abbott Laboratories, 1:07-cv-00081 (W.D. Va.); U.S. ex rel. Mulcahy v. Abbott Laboratories, 1:08-cv-0054 (W.D. Va.); U.S. ex rel. Dietzler v. Abbott Laboratories, 1:09-cv-00051 (W.D. Va.); U.S. ex rel. Spetter v. Abbott Laboratories, 1:10-cv-00006 (W.D. Va.).</ref><ref>{{Cite web|url=https://www.law360.com/articles/516296/abbott-shareholders-agree-to-settle-depakote-marketing-suit|title=Abbott, Shareholders Agree To Settle Depakote Marketing Suit - Law360|website=www.law360.com|access-date=5 July 2023|archive-date=4 March 2016|archive-url=https://web.archive.org/web/20160304072158/http://www.law360.com/articles/516296/abbott-shareholders-agree-to-settle-depakote-marketing-suit|url-status=live}}</ref> Following Abbott's spinoff of its research-based pharmaceuticals business, it no longer owns the commercial rights and associated responsibilities for Humira and Depakote.<ref>{{cite news|url=https://www.reuters.com/article/abbott/update-2-abbott-ultra-bullish-on-humira-despite-spinoff-plan-idUSN1E79K06F20111021|title=Abbott ultra-bullish on Humira despite spinoff plan|work=Reuters|date=21 October 2011|last1=Krauskopf|first1=Ransdell Pierson|access-date=22 November 2019|archive-date=20 August 2020|archive-url=https://web.archive.org/web/20200820201630/https://www.reuters.com/article/abbott/update-2-abbott-ultra-bullish-on-humira-despite-spinoff-plan-idUSN1E79K06F20111021|url-status=live}}</ref>